CEP, DMF and ASMF: Which Regulatory Route for Which Market

When a pharmaceutical company evaluates an active ingredient, one of the first practical questions is how the API will be documented in the dossier of the finished product. Three acronyms dominate the conversation: CEP, DMF and ASMF. They are not interchangeable, they are not available everywhere, and choosing the wrong route is one of the most common causes of delay in a registration timeline.

This article explains what each route is, where it applies and how the choice is usually made in practice.

What a CEP is and where it works

A Certificate of Suitability to the monographs of the European Pharmacopoeia, commonly called CEP, is issued by the EDQM. It certifies that the quality of an API produced by a specific manufacturer at a specific site is adequately controlled by the relevant pharmacopoeial monograph.

Its practical advantage is simplicity: where a CEP is accepted, the applicant for the finished product refers to it instead of submitting the full chemical documentation of the API. It is recognised in the European Union and in a number of countries that have adopted or reference the European Pharmacopoeia, which makes it a strong asset for products intended for several markets at once.

Its limits matter too. A CEP exists only where a monograph exists, it covers one manufacturing site, and any change at that site flows through a revision procedure that the applicant does not control.

ASMF: the European route without a CEP

Where no CEP is available, the European route is the Active Substance Master File. The ASMF is submitted in two parts: an applicant’s part, shared with the company registering the finished product, and a restricted part, sent directly to the authority and containing confidential manufacturing detail.

This two-part structure is the point of the system: it allows the API manufacturer to protect know-how while giving the authority everything it needs to assess quality. For the company registering the finished product, it means depending on the API manufacturer for the submission and maintenance of the restricted part, and for timely notification of any change.

DMF: the same logic, different jurisdiction

The Drug Master File is the equivalent instrument in the United States, filed with the FDA, with Type II covering drug substances. Other regulatory systems operate comparable mechanisms under their own names and rules.

The essential point is that a DMF is not automatically usable in Europe, and an ASMF is not automatically usable in the United States. The documentation may overlap substantially, but the procedures, formats and maintenance obligations differ.

How the choice is made in practice

The route is rarely chosen in the abstract. It is determined by three factors, in this order:

• The destination markets. A product intended for the European Union, a Gulf market and Latin America will be assessed against three different sets of expectations.
• What the API manufacturer already holds. If the site has a valid CEP, that usually settles the question for Europe. If it does not, the ASMF route becomes the working assumption.
• The timeline. Obtaining a new CEP is a procedure with its own duration. When time matters, an existing documentation package often outweighs a theoretically preferable route.

A fourth factor is less visible but decides many projects: the willingness of the API manufacturer to maintain the file properly over the years, answer authority questions and notify changes in time. A perfect dossier with an unresponsive holder is a liability.

Questions worth asking before committing

• Does the site hold a valid CEP for this molecule, and what is its revision history?
• Has an ASMF or DMF already been submitted, in which countries, and with what outcome?
• Who handles authority questions on the restricted part, and in what timeframe?
• How are variations communicated to customers who have the product registered?

Where sourcing and regulatory work meet

In practice the regulatory route and the commercial decision cannot be separated: the same molecule from two different sites can mean two different registration timelines. Synergy Swiss Pharma assesses both aspects together, verifying what documentation exists for the intended market before a product is proposed, and coordinating with the manufacturing site during the registration process.

Related questions on documentation and market availability are answered in the FAQ section, and the current product categories are listed under generics and the other therapeutic areas.